Armata Pharmaceuticals
ARMP
24 hedge funds and large institutions have $5.93M invested in Armata Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 3 closing their positions.
42% more capital invested
Capital invested by funds: $4.17M → $5.93M (+$1.76M)
0.36% more ownership
Funds ownership: 3.57% → 3.93% (+0.36%)
4% less funds holding
Funds holding: 25 → 24 (-1)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$318K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$65K |
| 3 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$53K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$7.96K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.05K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4.16K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.07K |
| 5 |
LFG
Larson Financial Group
St Louis,
Missouri
|
-$3.13K |
ARMP Hedge Fund Activity: Q1 2024 in Review
24 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2024, worth a combined $5.93M — up 42% from $4.17M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ARMP and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $318K. The largest seller was Renaissance Technologies, cutting an estimated $7.96K.
- 24 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2024, down from 25 in Q4 2023.
- Funds reported $5.93M of Armata Pharmaceuticals stock for Q1 2024, up 42% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Armata Pharmaceuticals buyer in Q1 2024 was Susquehanna International Group, an estimated $318K added.
- The largest Armata Pharmaceuticals seller in Q1 2024 was Renaissance Technologies, an estimated $7.96K sold.
Based on aggregated 13F filings for Q1 2024.